Table 1.
Baseline characteristics of patients with bipolar depression whether given antidepressants or not across the 5 data sources
| IQVIA DA France | IQVIA DA Germany | IQVIA US Hospital CDM | IQVIA US Open Claims | Beijing Anding | Pooled from 5 databases | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AD | Non-AD | AD | Non-AD | AD | Non-AD | AD | Non-AD | AD | Non-AD | AD | Non-AD | |
| Sample size | 502 | 682 | 1,077 | 2,696 | 3,072 | 14,249 | 69,274 | 30,398 | 504 | 389 | 74,429 | 48,414 |
| Age, mean (SD) | 52.67 ± 14.37 | 50.55 ± 15.26 | 53.11 ± 15.27 | 51.70 ± 16.57 | 49.2 ± 14.46 | 45.74 ± 15.14 | 44.9 ± 16.22 | 46.90 ± 18.71 | 39.0 ± 16.21 | 35.56 ± 14.86 | 47.80 ± 15.31 | 46.21 ± 16.14 |
| Male, n (%) | 188 (37.5) | 201 (29.5) | 412 (38.3) | 1,036 (38.4) | 819 (26.7) | 4,161 (29.2) | 19,840 (28.6) | 12,016 (39.5) | 208 (41.3) | 166 (42.7) | 21,467 (28.8) | 17,580 (36.3) |
| Previous manic episodes, n (%) | 7 (1.4) | 22 (3.2) | 122 (11.3) | 296 (11) | 195 (6.4) | 928 (6.5) | 6,740 (9.7) | 2,982 (9.8) | 135 (26.8) | 132 (33.9) | 7,199 (9.6) | 4,360 (9) |
| Mood stabilizers, n (%) | 133 (26.5) | 196 (28.7) | 370 (34.4) | 700 (26) | 1,454 (47.3) | 653 (4.6) | 35,676 (51.5) | 5,393 (17.7) | 307 (60.9) | 233 (59.9) | 37,940 (51.0) | 7,175 (14.8) |
| Lithium, n (%) | NA | NA | 170 (15.8) | 357 (13.2) | 368 (12) | 215 (1.5) | NA | NA | 172 (34.1) | 160 (41.1) | 710 (15.3) | 732 (4.2) |
| Divalproex, n (%) | 83 (16.5) | 118 (17.3) | 102 (9.5) | 175 (6.5) | 544 (17.7) | 254 (1.8) | 12,130 (17.5) | 1,869 (6.2) | 242 (48) | 169 (43.4) | 13,101 (17.6) | 2,585 (5.3) |
| Lamotrigine, n (%) | 40 (8) | 63 (9.2) | 130 (12.1) | 225 (8.4) | 685 (22.3) | 218 (1.5) | 26,283 (37.9) | 3,633 (12) | 24 (4.8) | 29 (7.5) | 27,162 (36.5) | 4,168 (8.6) |
| Carbamazepine, n (%) | 21 (4.2) | 25 (3.7) | 20 (1.9) | 41 (1.5) | 100 (3.3) | 48 (0.3) | 2,979 (4.3) | 331 (1.1) | NA | NA | 3,120 (4.2) | 445 (0.9) |
| Olanzapine/fluoxetine (Symbyax) or lurasidone or quetiapine or cariprazine, n (%) | 51 (10.2) | 80 (11.7) | 279 (25.9) | 557 (20.7) | 964 (31.4) | 343 (2.4) | 31,305 (45.2) | 4,143 (13.6) | 191 (37.9) | 145 (37.3) | 32,790 (44.1) | 5,268 (10.9) |
| Antipsychotics, n (%) | 168 (33.5) | 244 (35.8) | 409 (38) | 807 (29.9) | 2,026 (66) | 1,074 (7.5) | 49,524 (71.5) | 7,618 (25.1) | 317 (62.9) | 257 (66.1) | 52,444 (70.5) | 10,000 (20.7) |
| First-generation antipsychotics, n (%) | 28 (5.6) | 46 (6.7) | 41 (3.8) | 62 (2.3) | 693 (22.6) | 499 (3.5) | 7,689 (11.1) | 1,106 (3.6) | 52 (10.3) | 41 (10.5) | 8,503 (11.4) | 1,754 (3.6) |
| Second-generation antipsychotics, n (%) | 156 (31.1) | 223 (32.7) | 392 (36.4) | 785 (29.1) | 1,823 (59.3) | 705 (5) | 48,145 (69.5) | 7,058 (23.2) | 307 (60.9) | 252 (64.8) | 50,823 (68.3) | 9,023 (18.6) |
AD, antidepressants; NA, the proportion is less than 0.1%.